Sandbox Reserved 1658: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Lucas Bisel (talk | contribs) No edit summary |
Lucas Bisel (talk | contribs) No edit summary |
||
| Line 51: | Line 51: | ||
== Applications == | == Applications == | ||
<p align="justify">NRP1 targeting is investigated as a possible cancer therapy. Several methods have been developed to inhibit the oncogenic activities of NRP1 by using iRNA, monoclonal antibodies or even peptides. Especially, monoclonal antibodies are experimented as antitumor agents. Some have already being developed such as specific CUB antibodies and anti-NRP1B that inhibit cell migration induced by VEGF and the formation of tumors in endothelial cells.</p> | <p align="justify">NRP1 targeting is investigated as a possible cancer therapy <ref name="therapy">PMID: 24263240</ref>. Several methods have been developed to inhibit the oncogenic activities of NRP1 by using iRNA <ref name="applications">DOI 10.3892/etm.2018.6234</ref>, monoclonal antibodies or even peptides. Especially, monoclonal antibodies are experimented as antitumor agents. Some have already being developed such as specific CUB antibodies<ref name="applications"/> and anti-NRP1B<ref name="applications"/> that inhibit cell migration induced by VEGF and the formation of tumors in endothelial cells.</p> | ||
== References == | == References == | ||
<references/> | <references/> | ||
